Virtual Obesity Treatment Program Led to Substantial Weight Loss in Real-World Study
DALLAS — A real-world virtual obesity treatment program that involved use of GLP-1 receptor agonists with intensive lifestyle interventions led to robust and sustained weight loss, according to an analysis of a cohort study. At 12 months, there was an average weight loss of 16.2% of body weight, with results sustained up to 24 months, […]
Chronic Cough Drug Shows Some Benefit, but Taste-Related Events an Issue
MILAN — Twice-daily doses of the oral P2X3 receptor antagonist gefapixant may improve refractory or unexplained chronic cough, but at the cost of adverse events, a meta-analysis and systematic review found. Moderate-certainty evidence indicated that a 45-mg dose led to a small (17.6%, 95% CI 10.6-24.0) decrease in awake cough frequency, a small (16.0%, 95% […]
Low-Dose Semaglutide Can Ease Insulin Need in Early T1D, Small Series Shows
When used very early on in type 1 diabetes, a GLP-1 receptor agonist may help reduce the need for insulin, a small case series suggested. Ten adults with a new type 1 diabetes diagnosis initially received a 0.125-mg dose of weekly semaglutide (Ozempic), which was adjusted up to a maximum of 0.5 mg per week […]
FDA Greenlights New Myasthenia Gravis Drug
The FDA approved rozanolixizumab-noli (Rystiggo), a neonatal Fc receptor blocker, to treat adults with generalized myasthenia gravis (gMG), UCB announced Tuesday. The drug is the first approved to treat both of the two most common subtypes of gMG patients — those who are anti-acetylcholine receptor (AChR)-positive and those who are anti-muscle-specific tyrosine kinase (MuSK) antibody-positive. […]
Novel Triple Agonist Nabs Biggest Weight Loss Yet in Obesity Trial
SAN DIEGO — An investigational triple-hormone receptor agonist yielded major weight loss in people with obesity, a phase II trial showed. By 24 weeks, patients on any of the four doses of once-weekly injectable retatrutide lost a significantly greater amount of weight than those on placebo — achieving the trial’s primary endpoint — reported Ania […]
Near 15% Weight Loss With Novel Oral GLP-1 RA in Phase II Obesity Trial
SAN DIEGO — Orforglipron, an investigational nonpeptide GLP-1 receptor agonist, helped people with obesity lose a significant amount of weight in a phase II trial. Tested at four once-daily doses — 12, 24, 36, or 45 mg — patients on orforglipron lost between 8.6% to 12.6% of body weight compared with a 2% change seen […]
Another Online SARMs Retailer Gets a Warning From the FDA
The FDA issued a warning letter to an online retailer selling multiple selective androgen receptor modulators (SARMs) earlier this month, in an ongoing effort to curb their use in consumers, the agency said. This recent letter advised a California-based company, known as Warrior Labz SARMS, and its owner, Jeremy Brown, to stop actively marketing SARMs […]
Base-Edited CAR-T Product ‘Potent’ in Relapsed Childhood T-Cell ALL
The use of base editing to generate universal off-the-shelf chimeric antigen receptor (CAR) T cells in patients with relapsed T-cell acute lymphoblastic leukemia (ALL) should be further investigated based on promising interim results from a phase I study. In one of three patients — a 13-year-old girl who had relapsed T-cell ALL after allogeneic stem […]
Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer
CHICAGO — Upfront CDK4/6 inhibition or second-line use in advanced hormone receptor (HR)-positive/HER2-negative breast cancer led to similar cumulative progression-free survival (PFS) in a large randomized trial. Patients who received a CDK4/6 inhibitor plus an aromatase inhibitor (AI) as initial therapy and fulvestrant in the second line had a median PFS of 31.0 months at […]
Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma
CHICAGO — Patients treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) in the second line for early relapsed or refractory large B-cell lymphoma had significantly longer overall survival (OS) than those treated with standard care, according to an analysis of the ZUMA-7 trial. At a median follow-up of 47.2 months […]